Allworth Financial LP Has $35.14 Million Stock Position in Abbott Laboratories $ABT

Posted by Stanley Muller on May 14th, 2026

Allworth Financial LP raised its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 5.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 280,467 shares of the healthcare product maker’s stock after purchasing an additional 13,984 shares during the quarter. Allworth Financial LP’s holdings in Abbott Laboratories were worth $35,140,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Harbor Capital Advisors Inc. bought a new stake in Abbott Laboratories in the fourth quarter valued at approximately $27,000. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories during the third quarter worth $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at $31,000. Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $33,000. Finally, Copia Wealth Management acquired a new stake in Abbott Laboratories during the 3rd quarter worth $38,000. 75.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of research analyst reports. Sanford C. Bernstein decreased their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. JPMorgan Chase & Co. dropped their price target on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Stifel Nicolaus decreased their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Oppenheimer lowered their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, TD Cowen dropped their target price on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $119.43.

Get Our Latest Stock Analysis on ABT

Abbott Laboratories Stock Down 0.6%

NYSE:ABT opened at $83.83 on Thursday. The stock has a 50-day simple moving average of $100.17 and a 200 day simple moving average of $113.85. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06. The company has a market cap of $146.02 billion, a PE ratio of 23.48, a PEG ratio of 1.41 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 3.0%. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by insiders.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Recent insider-buying coverage highlighted Abbott alongside other companies with insider purchases, which can be interpreted as a sign of confidence from management or executives. Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell (ABT)
Positive Sentiment: Wall Street sentiment remains relatively constructive, with articles noting that analysts are still broadly optimistic on Abbott and that the stock’s dividend yield has risen to a decade-high level, which may attract value-oriented investors. Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Neutral Sentiment: Abbott is also being highlighted in broader healthcare and regenerative-medicine market research, reinforcing that it remains a major player in long-term growth markets, though this is not an immediate stock catalyst. Australia Regenerative Medicine Market Research Trends and Forecasts Report 2026-2035 Featuring Prominent Players Such as Abbott Laboratories, Astellas Pharma, and Roche
Negative Sentiment: Investors remain focused on Abbott’s post-earnings weakness, including concerns about Exact Sciences dilution, legal risks, and soft diagnostics trends, which have weighed on sentiment and helped keep shares depressed. Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?
Negative Sentiment: Older commentary also pointed to Abbott trading at a low valuation after the Exact Sciences deal and legal judgments, suggesting the market is still discounting uncertainty around earnings quality and integration costs. Abbott’s dividend yield near decade peak, signaling rare buying opportunity

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.